

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

February 2019

Vol. 47, No. 2

## CONTENTS

### MINIREVIEW

- Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017. *Jingjing Yu, Ichiko D. Petrie, René H. Levy, and Isabelle Ragueneau-Majlessi* . . . . . 135

### ARTICLES

- Development and Characterization of MDR1 (*Mdr1a/b*) CRISPR/Cas9 Knockout Rat Model. *Chenmeizi Liang, Junfang Zhao, Jian Lu, Yuanjin Zhang, Xinrun Ma, Xuyang Shang, Yongmei Li, Xueyun Ma, Mingyao Liu, and Xin Wang* . . . . . 71
- Serotonin Receptors of 5-HT<sub>2</sub> Type in the Hypothalamic Arcuate Nuclei Positively Regulate Liver Cytochrome P450 via Stimulation of the Growth Hormone–Releasing Hormone/Growth Hormone Hormonal Pathway. *Ewa Bromek, Marta Rysz, Anna Haduch, and Władysława A. Daniel* . . . . . 80
- Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation. *Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha, and Andrew D. Patterson* . . . . . 86
- Extrapolation of In Vivo Hepatic Clearance from In Vitro Uptake Clearance by Suspended Human Hepatocytes for Anionic Drugs with High Binding to Human Albumin: Improvement of In Vitro-to-In Vivo Extrapolation by Considering the “Albumin-Mediated” Hepatic Uptake Mechanism on the Basis of the “Facilitated-Dissociation Model”. *Soo-Jin Kim, Kyeong-Ryoon Lee, Seiji Miyauchi, and Yuichi Sugiyama* . . . . . 94

- Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers. *Chun Yang, Dongmei Zhou, Zancang Shen, David M. Wilson, Matthew Renner, Jeffrey N. Miner, Jean-Luc Girardet, and Caroline A. Lee* . . . . . 104

- Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals. *Hidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, Koki Kojima, Akihito Ogasawara, Yoshinobu Nakamaru, and Hiroshi Yamazaki* . . . . . 114

- Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry. *Justine Badée, Nahong Qiu, Neil Parrott, Abby C. Collier, Stephan Schmidt, and Stephen Fowler* . . . . . 124

- Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. *Terry Podoll, Paul G. Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, Hao Sun, Mark Gohdes, Kristen Cardinal, Mitesh Sanghvi, and J. Greg Slatter* . . . . . 145

- Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. *James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock, and Kim L. R. Brouwer* . . . . . 155

Downloaded from dmd.aspetjournals.org at ASPET Journals on February 22, 2019

Continued on next page

- ☐ Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives. *Divya Muthiah, Georgia K. Henshaw, Aaron J. DeBono, Ben Capuano, Peter J. Scammells, and Richard Callaghan* . . . . . **164**

**SHORT COMMUNICATION**

- ☐ Identification of 19-(*S/R*)Hydroxyeicosatetraenoic Acid as the First Endogenous Noncompetitive Inhibitor of Cytochrome P450 1B1 with Enantioselective Activity. *Sherif M. Shoieb, Ahmed A. El-Sherbeni, and Ayman O. S. El-Kadi* . . . . . **67**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

*About the cover:* Remodeling of the gut microbiota by BBR leads to a change in the composition of bile acids and associated activation of FXR signaling. See the article by Tian et al. ([dx.doi.org/10.1124/dmd.118.083691](https://doi.org/10.1124/dmd.118.083691)).